Origin: Where the Research Comes From BPC-157 was first isolated and characterized as a fragment of a larger ~40-kDa cytoprotective protein identified in human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb, Croatia
unregulated and alone is the single biggest safety factor in the whole conversation
NO-related findings have been explored across multiple tissue and cell-type contexts, including gastrointestinal, endothelial, fibroblast, vascular, and neuronal model systems
Species-specific factors profoundly influence both efficacy and safety profiles
Treatment regimens typically include more frequent injections initially (e.g., three times weekly for two weeks in non-neurological deficiency
Regular monitoring may be appropriate for patients with chronic conditions, ensuring stability and detecting any disease progression